Close

What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Additionally, the College of American Pathologists (CAP)  has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.

Team

CPIC Co-Principal Investigators
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Teri E. Klein, Ph.D.
Stanford University

Co-Investigator
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University

James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital

Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University

Steering Committee

Teri E. Klein, Ph.D.
Stanford University

Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Michelle Whirl-Carrillo, Ph.D.
Stanford University

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

Dan M. Roden, M.D.
Vanderbilt University

Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH

Larissa Cavallari, Pharm.D.
University of Florida

Stuart Scott, Ph.D.
Icahn School of Medicine at Mount Sinai

Sara Van Driest, M.D., Ph.D.
Vanderbilt University

Scientific Advisory Board

Julie A. Johnson, Pharm.D.
University of Florida

Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories

Robert Nussbaum, M.D.
University of California, San Francisco

Heidi Rehm, Ph.D.
Partners Healthcare

Marc S. Williams, M.D.
Geisinger

Sandy Aronson
Partners Personalized Medicine

Justin B. Starren, M.D., Ph.D.
Northwestern University

  • CPIC Guideline update: HLA-B/CYP2C9 and Phenytoin/Fosphenytoin September 8, 2020
    The 2020 CPIC Guideline update for HLA-B, CYP2C19 and phenytoin dosing is now published in Clinical Pharmacology and Therapeutics. The accepted article can be accessed on the PharmGKB page for phenytoin and on the CPIC website. Phenytoin is an antiepileptic drug with inter-individual pharmacokinetic variability, partly due to CYP2C9 genetic variation, and  a narrow therapeutic index. The presence of the HLA-B*15:02 variant allele is associated with an increased risk of phenytoin-induced cutaneous adverse reactions of Stevens-Johnson […]
  • PharmGKB and CPIC Partner with ClinGen August 27, 2020
    PharmGKB and CPIC have formalized a partnership with ClinGen to bring pharmacogenomics (PGx) expertise to the primarily disease-focused, NIH-funded mega-resource.  ClinGen's goals include defining the clinical relevance of genes and variants for use in precision medicine and research and disseminating that knowledge to the broader community.  They have developed and implemented data standards for clinical […]
  • New CPIC Guideline: CYP2C19 and Proton Pump Inhibitors (PPIs) August 12, 2020
    The CPIC Guideline for CYP2C19 and proton pump inhibitor (PPI) dosing is now published in Clinical Pharmacology and Therapeutics. The accepted article can be accessed on the PharmGKB page for omeprazole, lansoprazole, pantoprazole, dexlansoprazole, and on the CPIC website. PPIs inhibit the final pathway of acid production, which leads to inhibition of gastric acid secretion. PPIs are widely used in the treatment and prevention of many conditions including […]
  • PharmVar user survey released July 30, 2020
    The Pharmacogene Variation (PharmVar) Consortium, a central repository for pharmacogene (PGx) variation that focuses on haplotype structure and allelic variation is interested in hearing from the PGx user community regarding their resource.  Please take a couple of minutes to fill out their user survey.
  • ICPC publishes GWAS analysis on platelet reactivity and cardiovascular response in patients treated with clopidogrel July 10, 2020
    The GWAS analysis on platelet reactivity and cardiovascular outcome for clopidogrel, the third paper by the International Clopidogrel Pharmacogenomics Consortium (ICPC), has just been published in journal Clinical Pharmacology & Therapeutics.Clopidogrel is an antiplatelet agent widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Individual responses to clopidogrel show substantial variability, and poor […]